Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial

Fuji, Takeshi; Wang, Ching‐Jen; Fujita, Shinya; Kawai, Yohko; Nakamura, Mashio; Kimura, Takeshi; Ibusuki, Kei; Ushida, Hitoshi; Abe, Kenji; Tachibana, Shinya

doi:10.1016/j.thromres.2014.09.011

Cited by 134 publications

(130 citation statements)

References 24 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…Primary prophylaxis of VTE Two phase III randomised trials comparing edoxaban versus enoxaparin for thromboprophylaxis after total knee (Studying Thrombosis After Replacement Surgery (STARS)-E3) [29] or hip (STARS-J5) [30] replacement demonstrated that edoxaban efficacy was similar (STARS-J5) or superior (STARS-E3) to that of enoxaparin, with a comparable safety profile.…”

Section: Edoxabanmentioning

confidence: 99%

Direct oral anticoagulants and venous thromboembolism

Franchini

Mannucci

2016

Eur Respir Rev

View full text Add to dashboard Cite

Venous thromboembolism (VTE), consisting of deep vein thrombosis and pulmonary embolism, is a major clinical concern associated with significant morbidity and mortality. The cornerstone of management of VTE is anticoagulation, and traditional anticoagulants include parenteral heparins and oral vitamin K antagonists. Recently, new oral anticoagulant drugs have been developed and licensed, including direct factor Xa inhibitors (e.g. rivaroxaban, apixaban and edoxaban) and thrombin inhibitors (e.g. dabigatran etexilate). This narrative review focusses on the characteristics of these direct anticoagulants and the main results of published clinical studies on their use in the prevention and treatment of VTE. @ERSpublications Direct oral anticoagulants represent an addition for the management of VTE

show abstract

Section: Edoxabanmentioning

confidence: 99%

Direct oral anticoagulants and venous thromboembolism

Franchini

Mannucci

2016

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…Two pivotal, randomized, double-blind, multicenter, phase III trials compared edoxaban 30 mg qd to enoxaparin in knee surgery, STARS E-III [55], and hip surgery, STARS J-V [57]. In both STARS E-III and STARS J-V edoxaban 30 mg qd was superior to enoxaparin in the preventions of VTE, with comparable rates of bleeding [55,57].…”

Section: Venous Thromboembolism Prevention In Major Orthopedic Surgerymentioning

confidence: 99%

“…In both STARS E-III and STARS J-V edoxaban 30 mg qd was superior to enoxaparin in the preventions of VTE, with comparable rates of bleeding [55,57]. Supported by the data from these phase III studies edoxaban was approved in Japan in April 2011 for the prevention of VTE following lower-limb orthopedic surgery.…”

Section: Venous Thromboembolism Prevention In Major Orthopedic Surgerymentioning

confidence: 99%

“…Patients were random- Data from [53][54][55][56][57] bid twice daily, CRNM clinically relevant non-major, DVT deep vein thrombosis, PE pulmonary embolism, qd once daily, VTE venous thromboembolism ized to edoxaban 30 mg od, 60 mg od, 30 mg bid, 60 mg bid, or warfarin (INR 2.0-3.0) [58]. A significantly higher incidence of major and/or CRNM bleeding was seen in the twicedaily edoxaban regimen (60 mg bid, 10.6 %, P = 0.002; 30 mg bid, 7.8 %, P = 0.029) than warfarin (3.2 %), however there were no significant differences between the warfarin and once-daily regimens.…”

Section: Stroke Prevention In Atrial Fibrillationmentioning

confidence: 99%

See 1 more Smart Citation

Factor Xa Inhibitors

Shantsila

Lip

2016

Non-Vitamin K Antagonist Oral Anticoagulants

View full text Add to dashboard Cite

“…STARS E-3 compared edoxaban ( 30 mg once daily started 6-24 hours after surgery ) wit enoxaparin 20 mg b.i,d, in 746 patients undergoing TKA [49] In STARS E-3 edoxaban decreased DVT in comparison to enoxaparin ( 2.4 vs 6.9%). Bleeding rate did not differ between the two drugs.…”

Section: Edoxabanmentioning

confidence: 99%

Prophylaxis of Venous Thromboembolism in Knee Replacement Surgery

Rostagno¹,

Carulli²,

Cartei³

et al. 2016

Prog Orthop Sci

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is still a frequent and sometimes severe complication after knee replacement surgery. Both pharmacological and non-pharmacological measures have been widely used to decrease VTE risk. Non pharmacological treatment include measures directed to decrease the effects of blood stasis, intermittent pneumatic compression device (IPCD) and graduated compression stockings, and mechanical devices. Pharmacological prophylaxis of venous thromboembolism (VTE) is associated with a more significant decrease in the incidence of deep venous thrombosis (DVT) and related complications after knee arthroplasty however anticoagulation may increase the risk of postoperative bleeding and related complications, in particular the need for re-intervention. Aim of present review was to suggest practical approach to DVT prophylaxis in patients undergoing knee arthroplasty. Although parenteral drugs (low dose unfractionated heparin, low molecular weight heparin and fondaparinux) are the more frequently employed agents, limited compliance may be a concern. Recent studies suggest that direct oral anticoagulants, antithrombin and anti Xa agent, might be a useful alternative although safety may limited by an higher rate of local bleeding.

show abstract

Safety and Efficacy of Edoxaban, an Oral Factor Xa Inhibitor, Versus Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty: The STARS E-3 Trial

Cited by 134 publications

References 24 publications

Direct oral anticoagulants and venous thromboembolism

Direct oral anticoagulants and venous thromboembolism

Factor Xa Inhibitors

Prophylaxis of Venous Thromboembolism in Knee Replacement Surgery

Contact Info

Product

Resources

About